Denis James Mintern - 03 Mar 2025 Form 4 Insider Report for CRH PUBLIC LTD CO (CRH)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
05 Mar 2025, 16:30:20 UTC
Prior SEC filing
02 Jan 2025
Next SEC filing
15 May 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Neil Colgan, Attorney-in-Fact for Denis James Mintern

Key filing fact

Denis James Mintern filed Form 4 for CRH PUBLIC LTD CO (CRH) on 05 Mar 2025.

Key facts

  • This page summarizes Denis James Mintern's Form 4 filing for CRH PUBLIC LTD CO (CRH).
  • 5 reported transactions and 2 derivative rows are listed below.
  • Accepted by SEC: 05 Mar 2025, 16:30.

Change

  • Previous filing in this sequence was filed on 02 Jan 2025.
  • Current net transaction value: -$880,439.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CRH transaction

Ordinary Shares

Award

Transaction value
$0
Shares
+8,554
Change %
+24%
Price
$0.000000
Shares after
44,183
Date
03 Mar 2025
Ownership
Direct
Footnotes
F1
CRH transaction

Ordinary Shares

Tax liability

Transaction value
$458,747
Shares
-4,457
Change %
-10%
Price
$102.93
Shares after
39,726
Date
03 Mar 2025
Ownership
Direct
Footnotes
F2, F3
CRH transaction

Ordinary Shares

Sale

Transaction value
$421,693
Shares
-4,097
Change %
-10%
Price
$102.93
Shares after
35,757
Date
03 Mar 2025
Ownership
Direct
Footnotes
F4, F5

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CRH transaction Derivative

Deferred Share Award

Options Exercise

Transaction value
$0
Shares
-7,837
Change %
-25%
Price
$0.000000
Shares after
22,916
Date
03 Mar 2025
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
7,837
Exercise price
$0.000000
Footnotes
F1
CRH transaction Derivative

Deferred Share Award

Award

Transaction value
Shares
+6,744
Change %
+29%
Price
Shares after
29,660
Date
03 Mar 2025
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
6,744
Exercise price
$0.000000
Footnotes
F6
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

Reflects the vesting and release of a 2022 time-based conditional award as defined in the 2014 Deferred Share Bonus Plan (the "DSB Plan Rules"), of which, pursuant to the determination of the Compensation Committee of the Board of Directors of the Issuer (the "Compensation Committee"), a total of 8,554 shares vested on March 3, 2025, including the award of 717 additional Ordinary Shares as dividend equivalents. Subject to the determination of the Compensation Committee, the remaining awards of 13,389 shares and 9,527 shares are expected to vest in March 2026 and March 2027, respectively. In accordance with the DSB Plan Rules, dividend equivalents will apply to these awards and, to the extent awarded, will be reported at the time of vesting.

Footnote F2

Mandatory sale of sufficient Ordinary Shares to cover applicable withholding tax liabilities arising in the connection with the aforementioned award.

Footnote F3

The reported price represents the volume-weighted average price of shares sold. Sale prices for the reported transaction ranged between $102.30 and $ 103.535 inclusive of shares sold on the New York Stock Exchange. Full information regarding the number of Ordinary Shares sold at each separate price in the range will be provided to the SEC upon request.

Footnote F4

The reported price represents the volume-weighted average price of shares sold. Sale prices for the reported transaction ranged between $102.30 and $103.535 inclusive of shares sold on the New York Stock Exchange. Full information regarding the number of Ordinary Shares sold at each separate price in the range will be provided to the SEC upon request.

Footnote F5

Includes 128 Ordinary Shares purchased by AC Employee Benefit Trustees Limited, as trustee for and on behalf of the Reporting Person, as sole beneficiary, pursuant to an Irish Revenue-approved broad-based employee share participation scheme. Such Ordinary Shares are subject to a minimum holding requirement of one year.

Footnote F6

Reflects a time-based conditional award, as defined in the DSB Plan Rules, of which, subject to the determination of the Compensation Committee, the balance will vest in March 2028. In accordance with the DSB Plan Rules, dividend equivalents will apply to the Award and, to the extent awarded, will be reported at the time of vesting.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .